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Abstract
Objective This study investigated the efficacy, safety,
tolerability, and pharmacokinetics of a novel cholesterol
absorption inhibitor, FM-VP4, comprising disodium
ascorbyl sitostanol phosphate (DASP) and disodium
ascorbyl campestanol phosphate (DACP).
Methods In phase 1, 30 men received a single dose of 100,
200, 400, 800, 1,600, or 2,000 mg FM-VP4 or placebo. In
phase 2, 100 men were treated with 100, 200, 400, or
800 mg/day of FM-VP4 or placebo for 4 weeks.
Results The drug was well tolerated at each single or mul-
tiple dose level. After 4 weeks of treatment, low-density
lipoprotein cholesterol (LDL-C) levels changed by 2.7% in
the placebo group and by 2.9%, −4.2%, and −4.6% in the
100, 200, and 800 mg/day groups, respectively, which was
not statistically significant. However, 400 mg/day of FM-
VP4 significantly decreased LDL-C by 6.5% (p= 0.02).
Phase 1 showed that DACP and DASP were absorbed into
plasma with a median tmax of 12 h for both components,
and clearance was slow with a mean t1/2λ of 57 h. During
4 weeks of treatment, steady state was reached by
approximately 8 days.
Conclusion This study demonstrated that up to 800 mg/day
of FM-VP4 is safe and well tolerated for at least 4 weeks.
Furthermore, the higher doses significantly reduced LDL-C
by 7% compared with baseline or by 10% compared with
placebo, with the maximum effect reached at 400 mg/day.
Keywords Hypercholesterolemia.Plantsterols.FM-VP4.
Safety.Pharmacokinetics
Introduction
Worldwide, cardiovascular disease (CVD) is the most
common cause of death, with atherosclerotic vascular
disease as the underlying cause. It has been well established
that elevated plasma concentrations of low-density lipo-
protein cholesterol (LDL-C) lead to an increased risk of
atherosclerosis and coronary heart disease [1]. Dietary
modification can improve the lipid profile and the potential
risk of CVD, but for a significant portion of the population,
treatment with lipid-lowering agents is necessary to reduce
blood cholesterol effectively. Statins are the primary class
of drugs used for managing LDL-C and are the most potent
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Utrecht, The Netherlandsagents in lowering LDL-C. In fact, the lowering of LDL-C
by statin therapy has been shown to decrease the number of
fatal and nonfatal myocardial events in both primary and
secondary prevention studies [2–6]. However, statins have
not provided the final answer in terms of CVD prevention,
and their use is associated with side effects, albeit rare, at
higher doses. Therefore, cholesterol-lowering agents that
act via other mechanisms are of great interest.
Plant sterols, or phytosterols, are naturally occurring
compounds invegetableoil,seeds,andnutsthatarestructurally
related to cholesterol. Daily intake of 2,000 mg of plant sterols
or their saturated counterparts, plant stanols, or phytostanols,
has been shown to decrease LDL-C by 9–14% without
affecting high-density lipoprotein cholesterol (HDL-C) con-
centrations [7, 8]. Plant sterols and stanols are thought to
decrease plasma cholesterol concentrations by inhibiting
cholesterol absorption in the intestine [9]. When cholesterol
absorption is decreased, the hepatic cholesterol pool is
reduced, resulting in enhanced cholesterol synthesis by the
liver. At the same time, LDL receptors are upregulated, with
ensuing lower LDL-C concentrations in plasma [10].
A new water soluble plant stanol derivative, disodium
ascorbyl phytostanol phosphate (FM-VP4, Fig. 1) has been
developed as a cholesterol-absorption inhibitor. FM-VP4
consists of a mixture of sitostanol and campestanol to
which ascorbate is covalently bound via a phosphodiester
linkage. It has been shown to inhibit the in vitro uptake of
micellar [
3H]-cholesterol by approximately 50% in human
and rat enterocyte cell lines [11, 12]. In vivo, FM-VP4 led
to a dose-related inhibition of [
3H]-cholesterol absorption in
rats, as shown by a maximally 80% reduced area under the
concentration time curve (AUC) of orally administered
micellar [
3H]-cholesterol [13]. Furthermore, the LDL-
lowering activity of FM-VP4 was observed in a broad range
of LDL-sensitive species, including gerbils [14, 15], ham-
sters [16], and apolipoprotein E (ApoE)-deficient transgenic
mice [17]. In hamsters, FM-VP4 was a more potent LDL-
lowering agent than unesterified plant stanols [16], and in
ApoE deficient mice, the LDL-lowering effect of FM-VP4
was correlated with retardation of atherosclerotic plaque
development [17]. Other effects of FM-VP4 included the
decrease of plasma triglyceride levels and the reduction of
abdominal fat or body-weight gain in gerbils [14, 15] and
mice [18]. In all of these cases, FM-VP4 showed no side
effects to the animals tested.
Preclinical data suggested that FM-VP4 is a potent
cholesterol-lowering agent with no significant toxic effects.
Here, we report the first human study designed to assess the
efficacy, safety, tolerability, and pharmacokinetics of single
and multiple doses of this water-soluble plant stanol analogue.
Subjects and methods
Subjects
Subjects were recruited via advertisements in local news-
papers. The study protocol was carefully explained before
subjects were asked to give their written informed consent.
The study protocol was approved by the Institutional
Review Board of the Academic Medical Centre. Subjects
were eligible if they were male, 18–75 years old, healthy as
reviewed by medical history and physical examination, had
LDL-C concentrations ≥3.0 mmol/L during one of the
screening visits or at baseline and triglyceride (TG)
concentration ≤4.5 mmol/L at the first visit, had a body
mass index (BMI) <35 kg/m
2, and did not use any steroids,
β-blockers, corticosteroids, thiazide diuretics, or antiepi-
leptics. Subjects with a history of hypertension, arterial
diseases, diabetes mellitus type I or II, hypothyroidism,
obstructive biliary disorders, pancreatitis, collagen disor-
ders, or autoimmune disease were excluded, as were
subjects with history of malignancy during the previous 3
years, significant hepatic, renal, cardiac, or cerebral disease,
or plasma levels of hepatic transaminases higher than two
times the upper limit of normal (ULN). Subjects of phase 1
were not allowed to use any lipid-lowering drugs at
inclusion, and the use of plant sterol- or stanol-containing
products had to be discontinued at the inclusion visit.
Subjects of phase 2 had to discontinue the use of plant
sterol or stanol products or fish oils at the inclusion visit
and statin treatment 6 weeks (40 days) before the start of
study treatment. Thirty men participated in the phase 1 trial
and 100 men in phase 2.
Drugs
Two types of tablets were used: 100 mg oval FM-VP4
tablets or a matching placebo. Both investigational products
were supplied through Forbes Medi-Tech Inc. (Vancouver,
Canada). FM-VP4 is a semisynthetic esterified plant stanol
derivative produced as a disodium salt. The two major
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Fig. 1 Chemical structure of FM-VP4, composed of disodium
ascorbyl campestanol phosphate (R=CH3) and disodium ascorbyl
sitostanol phosphate (R=C2H5)
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phosphate (DASP) and disodium ascorbyl campestanol
phosphate (DACP) (Fig. 1), which are present in the
proportion of approximately 2:1, respectively.
Design
This single-center, double-blind, placebo-controlled, dose-
escalation trial comprised two parts: In phase 1, 30 men
received a single dose of FM-VP4. Five subjects were
assigned to each dose group (100, 200, 400, 800, 1,600, or
2,000 mg), and within each group, one subject was
randomly assigned to placebo. Once a complete cohort of
five subjects was treated and the safety parameters had been
reviewed, the following dose was initiated. In the subse-
quent phase 2 trial, 100 men were treated for 28 days
(4 weeks). Twenty-five subjects were assigned to each dose
group (100, 200, 400, or 800 mg/day), and within each
group, five subjects were randomly assigned to placebo.
The first five subjects in each cohort were hospitalized for 5
days. Escalation to the next dosing level was only allowed
once these five subjects completed treatment and all results
and safety data were evaluated.
Phase 1 A week before treatment, subjects visited the
hospital for screening. Informed consent was obtained,
and subjects underwent a physical examination. A fasting
blood sample was taken to measure lipids, biochemistry,
and hematology. Within 3 days before treatment, subjects
visited the hospital for another blood sample, and urinalysis
and electrocardiogram (EKG) were performed. If subjects
met all inclusion criteria, they were hospitalized for 24 h on
the day of treatment. In the morning, subjects’ weight,
supine blood pressure (BP), and heart rate were measured,
and a predose fasting blood sample was taken for baseline
safety parameters and pharmacokinetics. Subsequently,
subjects were administered one to 20 tablets containing
100 mg FM-VP4 each or placebo. Tablets were swallowed
with 250 mL of water. Breakfast followed 30 min later.
Weight, supine BP, and heart rate were recorded at 3, 6, 9,
and 12 h after dosing. A blood sample for pharmacokinetics
was taken 6 and 12 h after dosing. Any spontaneous
complaints were recorded as adverse events and closely
monitored. Subjects were detained overnight under obser-
vation, and 24 h after dosing, another blood sample was
taken for safety parameters and pharmacokinetics. Subjects’
weight, supine BP, and heart rate were measured, and
urinalysis and an EKG were performed. Once the EKG,
biochemistry, and hematology of the 24-h postdosing
sample had been reviewed, subjects were discharged from
the hospital. They returned to hospital 48, 96, and 144 or
168 h (6 or 7 days) after treatment for weight, supine BP,
and heart rate measurements and for a blood sample to
measure safety parameters and pharmacokinetics. At the
last visit, a final physical examination was performed.
Phase 2 Four to 8 weeks before treatment, subjects visited
the hospital for screening. Informed consent was obtained,
and subjects underwent a physical examination. A fasting
blood sample was taken to measure lipids, biochemistry,
and hematology. Subjects were instructed to follow a diet
adapted from the National Cholesterol Education Program
(NCEP) Step 1 diet during the entire study, including the 4-
to 8-week run-in period. Consumption of plant sterol- or
stanol-containing products and the use of fish oils had to be
discontinued at the screening visit, and statin treatment had
to be discontinued 6 weeks before treatment with FM-VP4.
If they met all inclusion criteria, subjects visited the
hospital halfway through the run-in period and within 3
days before study treatment for baseline blood lipids,
biochemistry, and hematology measurements. At the latter
visit, urinalysis was performed and an EKG recorded.
The first five subjects per dose cohort, of which four
were on active treatment and one on placebo, were
hospitalized for 5 days. Each morning, subjects’ weight,
supine BP, and heart rate were measured, and a predose
fasting blood sample was taken for safety parameters and
pharmacokinetics. Subsequently, subjects were adminis-
tered one to four tablets containing 100 mg FM-VP4 each,
depending on the dose cohort, or placebo. Tablets were
swallowed entirely with up to 100 mL of water. Breakfast
followed 30 min later. All doses were divided and given
twice per day; another one to four tablets were administered
30 min before dinner. The morning and evening doses were
packaged in separate bottles. Subjects in the 100-mg group
received one FM-VP4 tablet and one placebo tablet. Supine
BP and heart rate were also recorded daily after lunch and
dinner. Any spontaneous complaints were recorded as
adverse events and closely monitored. Subjects were
observed overnight and discharged 5 days after the first
dosing. All subjects visited the hospital for efficacy and
safety measurements once per week during and 14 days
after treatment. At the last visit, a final physical examina-
tion and an EKG were performed. Compliance was
calculated based on the number of tablets supplied to the
patient minus the number returned.
Plasma analyses
Complete blood count, fibrinogen, and the biochemical
profile [alanine aminotransferase (ALT) and aspartate
aminotransferase (AST), bilirubin, creatine kinase (CK),
creatinine, glucose, and C-reactive protein (CRP)] were
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laboratory parameters were considered abnormal in case of
ALT or AST levels greater than three times ULN, a CK
level greater than five times ULN, a creatinine increase of
≥40 μmol/L compared with baseline, a creatinine level
>177 μmol/L, white blood cell count <3×10
9/L, and a
decrease in hemoglobin of at least 1.5 g/dL compared with
baseline. Thyroid-stimulating hormone (TSH) was mea-
sured at the first screening visit. Urinalysis for blood,
glucose, protein, pH, and specific gravity was performed by
dipstick within 3 days before and 1 day after dosing in
phase 1 and within 3 days before, after 4 weeks of
treatment, and at the last visit of phase 2. Urinalysis by
wet microscopic slide was performed if the dipstick
analysis was abnormal. Lipid analyses were performed by
an external laboratory (MRL International, Zaventem,
Belgium) by using standardized procedures, and LDL-C
was calculated using the Friedewald equation [19]. The
results were kept blinded to the investigators.
Plasma was stored at −80°C for further analyses. ApoB,
ApoAI, and lipoprotein a [Lp(a)] as well as vitamin E and
vitamin Awere analyzed in one run after the study had been
completed. ApoAI, ApoB, and Lp(a) levels were deter-
mined by nephelometry with a Beckman Array (Mijdrecht,
the Netherlands) according to the manufacturer’s instruc-
tions, and vitamin E and vitamin A were measured by
high-performance liquid chromatography (HPLC) with fluo-
rescence detection using a Chromsep Glass, 100*3 mm,
inertsil 5, ODS-3 column (Varian-Chrompack, Middelburg,
the Netherlands).
All DASP and DACP plasma concentrations were
assayed by a validated liquid chromatography/mass spec-
trometry/mass spectrometry method (LC/MS/MS) based on
a previously described method [20]. The lower limit of
quantification (LLOQ) was 30.8 ng/mL. Data analysis was
carried out using Microsoft Excel 97, and pharmacokinetic
data was analyzed using Pharsight WinNonlin software,
version 3.1 build 168 (Pharsight WinNonlin, Mountain
View, CA, USA) based on noncompartmental kinetics
analysis. For phase 1, concentrations of DASP and DACP
in plasma were measured at baseline and 6, 12, 24, 48,
96, and 144 or 168 h after treatment. DASP and DACP
concentrations were plotted against time, and the half-lives
of the compounds were estimated by the method of
residuals. The area under the DACP and DASP concen-
tration time curve (AUC 0-t) was estimated by the
trapezoidal rule [21]. In phase 2, trough concentrations of
DASP and DACP were measured at baseline, after 8 and
28 days of treatment, and 14 days after treatment (day
42). In subjects who were hospitalized for the first 5 days
of treatment, trough DASP and DACP concentrations
were also measured each morning of hospitalization (day
1 through day 5).
Plant sterols and stanols β-sitosterol, campesterol,
sitostanol, and campestanol were assessed by selective
ion monitoring gas chromatography mass spectrometry
(SIM-GC-MS). High-purity solvents were purchased from
Merck, Germany. Bis-(Trimethylsilyl)trifluoroacetamide
(BSTFA) was obtained from Sigma (Steinneim, Germany)
and pyridine from Pierce (Rockford, IL, USA). Beta-sitosterol
(24β-ethylcholesterol), β-sitostanol (24α-ethyl-5α-cholestan-
3β-ol), and campesterol (24α-methyl-5-cholesten-3β-ol)
were purchased from Sigma, and stigmasterol from Lacoclau
AB, Sweden. For sterol extraction, 500 μl of plasma was
mixed with 100 μl 0.01 mg/ml stigmasterol and saponified
for 60 min at 60°C in 1 ml of 4% (w/v) KOH in 90% ethanol.
After saponification, the samples were mixed with 1 ml of
water and extracted two times with 2 ml of hexane. The
pooled hexane extracts were dried under nitrogen and
derivatized with 50 μl BSTFA/pyridine (v/v 5:1) at 60°C
for 60 min. For SIM-GC-MS, 2 μl of derivative mixture
were delivered by automatic injection to an HP-5890 gas
chromatograph split-injection port (1:20) leading to a
0.2 mm×25 m Chrompack CP-sil 19 CB (WCOT Fused
Silica) capillary column. The injection port contained a
glass wool liner. The carrier gas was helium at a linear
rate of 1 ml/min. The oven temperature started at 120°C
and was raised to 260°C at 20°C/min, then to 280°C
at 2°C/min, and finally to 300°C at 40°C/min and held
for 5 min. An HP-5989B mass spectrometer was used
as detector. Measurements were done in the electron
impact mode at 70 eV with an ion source temperature
of 250°C. The quadropole temperature was 150°C. Mass
spectrometric data were collected in the elected ion mode
at m/z = 396 and 357 for β-sitosterol, m/z = 488 and 373 for
β-sitostanol, m/z = 382 and 343 for campesterol, m/z = 369
and 384 for campestanol, and m/z = 255 and 394 for
stigmasterol. Calibration curves were constructed by mix-
ing 100 μl of 0.01 mg/ml stigmasterol with a series of
0- to 500-μl samples of a standard solution containing
10 μmol β-sitosterol, 2 μmol/l sitostanol, and 20 μmol/l
campesterol.
Statistical analyses
The primary efficacy variable was the percent change in
LDL after 4 weeks of treatment compared with baseline
levels in phase 2. Differences in percentage LDL-C changes
between the five treatment groups were calculated using
analyses of variance (ANOVA) in SAS. P<0.05 was
considered statistically significant. If there was a significant
difference between dose groups by ANOVA, each active
dose was compared with placebo by a one-sided t test, with
p<0.025 being statistically significant. This procedure was
also performed for percentage changes in total cholesterol
(TC), HDL-C, and TG. For ApoB, ApoAI, Lp(a), vitamin A,
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to test differences in percentage changes between the five
treatment groups. Safety data are presented descriptively.
Results
In phase 1, 30 male volunteers completed the study in
accordance with the protocol. There were no withdrawals.
The majority of subjects (93%) were of Caucasian descent.
Mean subject age was 50.4 (range 24–63) years. In phase
2, 101 male subjects were enrolled, but one subject
withdrew consent prior to receiving study medication due
to personal reasons and therefore contributed no safety or
efficacy data. The remaining 100 subjects completed the
study. The majority of subjects (89%) were Caucasian,
with the remaining being Asian or another race. Mean
subject age was 53.7 (range 23–75) years. As calculated
from returned tablets, the mean percentage of received
tablets was 97%. One subject in the 800-mg group had a
compliance <80%. All other patients received >80% of the
planned number of tablets during the treatment period.
Five subjects received statin treatment within 40 days
before the first dose of study treatment (29–35 days).
Mean weight ranged between 83.9±13.1 and 84.6±13.0 kg
during the entire study.
Adverse events
In phase 1, 23 treatment-emergent adverse events were
reported by 16 subjects. Of these events, five (21.7%)
occurred in the 100-mg group, three (13.0%) in both the
200- and 400-mg groups, four (17.4%) in the 800-mg
group, two (8.7%) in the 1,600-mg group, and three
(13.0%) in both the 2,000 mg and placebo groups. All
reported events were mild. The most common events were
dizziness, headache, and fatigue. Other adverse events were
loose stools, vasovagal attack, influenza, upper respiratory
tract infection, elevated bilirubin, elevated BP, arthralgia,
difficult micturition, polyuria, and pharyngolaryngeal pain.
Three events were considered to be possibly related to the
study drug. One was reported by a subject receiving the
placebo treatment, whose bilirubin concentration increased
from 12 μmol/L on the morning of treatment (baseline) to
25 μmol/L 24 h after treatment but decreased to normal 7
days after treatment. The other two possibly related events
were reported in the 800- and 1,600-mg groups, and both
consisted of one episode of loose stools on the day of
treatment.
In phase 2, 67 subjects reported one or more treatment-
emergent adverse events: 12 in the 100-mg group, 14 in
the 200-mg group, 11 in the 400-mg group, 15 in the 800-
mg group, and 15 in the placebo group. Most events were
mild, and four subjects reported a moderate event. The
most frequent event was headache, which was reported by
a total of 19 subjects and by two (400-mg group) to five
subjects (100-mg and 200-mg groups) in each of the five
groups. The four adverse events that were moderate in-
cluded two subjects with headache in the 800-mg group,
one subject with an elevated CK level in the 400-mg group,
and one subject with epilepsy in the placebo group. No
subjects discontinued study treatment due to a treatment-
emergent adverse event. One subject in the 800-mg group
did not take the study medication for 3.5 days due to
nausea and diarrhea, which was not considered to have
been related to the study drug. Once the subject recom-
menced treatment, no further treatment-emergent adverse
events were reported.
A total of 24 subjects reported events that were
considered to be drug-related: eight in the 100-mg group,
one in the 200-mg group, two in the 400-mg group, six in
the 800-mg group, and seven in the placebo group. The
most commonly reported event was flatulence, which was
reported by three subjects in the 100-mg groups, one in the
400-mg group, two in the 800-mg group and one in the
placebo group. There were no differences in the incidence
of treatment-emergent adverse events between active and
placebo groups.
Blood pressure, heart rate, and EKG analysis
There was no effect of FM-VP4 on BP or heart rate during
phase 1. In phase 2, the mean systolic BP was slightly
decreased after 4 weeks of treatment (a maximum average
of 4% in the 100-mg group; data not shown), but there was
no relationship between this decrease and the dose of FM-
VP4. Diastolic BP did not change. All pre- and postdose
EKGs were normal in both phases of the trial.
Laboratory analyses
In phase 1, one subject in the placebo group showed a
bilirubin concentration increase from 12 μmol/L on the
morning of treatment (baseline) to 25 μmol/L 24 h after
treatment, as described in “Adverse events.” Seven days
after treatment, bilirubin concentration was reduced to
13 μmol/L. There were no other clinically significant
changes in hematology, biochemistry, plant sterols, or
urinalysis measurements, and there were no differences
between treatment groups. One subject who received
100 mg of FM-VP4 showed a decrease in white blood cell
(WBC) count from 6.2×10
9/L on the morning of treatment
(baseline) to 2.9×10
9/L 24 h after dosing. Seven days after
dosing, the WBC count recovered to 7.3×10
9/L. This event
was not considered to be clinically significant.
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phase 2. Four laboratory abnormalities were considered
clinically significant and were reported as adverse events.
Two subjects showed a decrease of WBC count. One sub-
ject in the 800-mg group had a level of 2.2×10
9/L at
screening, but those levels were increased to 5.8×10
9/L at
the following visit and remained normal during the rest
of the trial. This event was not considered clinically
significant. A subject in the 100-mg group had a WBC
count of 3×10
9/L at screening, and levels fluctuated
between 2.8×10
9/L and 4.6×10
9/L during the study. Two
subjects showed an increase in CK levels that was greater
than five times the ULN. In one of these patients, who was
in the 400-mg group, the event was recorded as an adverse
event of moderate severity. In the other subject, who was in
the placebo group, the event was not recorded as an adverse
event, as the patient had performed vigorous exercise the
previous day. Both subjects continued with medication, and
both had CK levels within normal limits at subsequent
measurements. Five subjects showed a decrease in hemo-
globin of a least 1.5 g/d (0.93 mmol/L): one each in the
100-mg, 200-mg, and 400-mg groups, and two in the
placebo group. However, those decreases occurred only
once, and levels were restored to normal at the subsequent
visit. Therefore, those changes were not considered clini-
cally significant.
There were no differences between treatment groups in
the changes of vitamin A and vitamin E concentrations at
week 4 compared with baseline (p= 0.32 and p = 0.38,
respectively; data not shown).
Overall, there were few abnormal laboratory values, and
no trends were observed over time. There appeared to be no
relationship between laboratory parameters and the dose of
FM-VP4 administered.
Efficacy
In phase 1, changes in lipids and lipoproteins were not
statistically compared between the seven treatment groups,
as only one dose of FM-VP4 was administered.
In the phase 2 run-in period, mean LDL-C levels were
3.94±0.71 mmol/L at 4–8 weeks before baseline, 4.19±
0.78 mmol/L halfway through the run-in period, and 4.16±
0.76 mmol/L at baseline. The absolute lipoprotein levels at
baseline and after 4 weeks of treatment per dose group and
the mean percentage change in LDL-C levels are presented
in Table 1. The percent changes of LDL-C by visit are also
depicted in Fig. 2. ANOVA analyses showed a borderline
statistically significant difference in the percentage change
in LDL-C and HDL-C, and pairwise comparisons between
each active dose and placebo revealed that 400 mg of FM-
VP4 reduced LDL-C significantly (p= 0.02). In the placebo
group, LDL-C increased by 2.7%, and in the 400-mg/day
group LDL-C reduced by 6.5%. There were no statistically
significant differences in percentage change of LDL-C
changes between the other active doses and placebo, and
Table 1 Plasma lipid and lipoprotein concentrations before and after 4 weeks of treatment with placebo or with 100 mg, 200 mg, 400 mg, or
800 mg/day of FM-VP4 (disodium ascorbyl campestanol phosphate and disodium ascorbyl sitostanol phosphate in phase 2 (n=20 per dose)
Dose level (mg) P value
a
Placebo 100 mg 200 mg 400 mg 800 mg
mmol/L
Total cholesterol Baseline 6.36±0.65 6.40±0.87 6.40±0.88 6.04±1.05 6.02±0.90
Day 28 6.50±0.72 6.49±1.12 6.26±0.78 5.81±1.05 5.90±0.90
% Change 2.6% 1.2% −1.7% −3.8% −1.7% 0.09
LDL Baseline 4.29±0.63 4.17±0.58 4.40±0.77 4.02±0.93 3.94±0.83
Day 28 4.38±0.79 4.28±0.78 4.18±0.63 3.75±0.88 3.73±0.81
% Change 2.7% 2.9% −4.2% −6.5%
b −4.6% 0.05
HDL Baseline 1.37±0.32 1.34±0.38 1.20±0.25 1.24±0.30 1.21±0.27
Day 28 1.37±0.37 1.29±0.34 1.28±0.31 1.22±0.27 1.26±0.37
% Change −0.1% −3.6% 6.7% −1.2% 4.1% 0.04
TG Baseline 1.56±0.77 1.86±1.30 1.77±0.72 1.73±0.72 1.92±0.68
Day 28 1.65±0.86 1.95±1.16 1.76±1.08 1.86±0.95 1.97±1.00
% Change 8.2% 16.3% 0.7% 7.5% 9.7% 0.8
All values are mean± standard deviation
LDL low-density lipoprotein, HDL high-density lipoprotein, TG triglycerides
aDifferences between all treatment groups were analyzed by using analysis of variance. If the difference between treatments was statistically
significant, then each active treatment group was individually compared with placebo
bP<0.025 (one-sided) as compared with the change in the placebo group
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centage change of HDL-C between any of the active doses
and placebo (Table 1). When statistical analysis was
carried out on a per-protocol basis and subjects who
were noncompliant (n=1) or who received statins within
40 days before study treatment (n=5) were excluded, a
dose-response in percentage change from baseline in LDL-
C was observed: changes in the placebo group and in the
100-, 200-, 400-, and 800-mg/day groups were 3.7%, 0.9%,
−4.1%, −6.9%, and −6.2%, respectively. When using these
per-protocol data, decreases in the 400- and 800-mg/day
groups were significantly different from placebo (p=0.007
and p=0.01, respectively). The percentage change in ApoB
at week 4 compared with baseline differed significantly
between treatment groups (p 0.007). Absolute changes in
ApoB were 0.017, 0.063, −0.058, −0.047, and −0.038 g/L
in the placebo, 100-, 200-, 400-, and 800-mg/day group,
respectively. There were no differences between treatment
groups in ApoAI and Lp(a) changes at week 4 compared
with baseline (data not shown).
Pharmacokinetics
In the 100- and 200-mg cohorts of phase 1, the majority of
plasma samples had DASP and DACP concentrations
below detection level. Therefore, the AUC 0→t and the
plasma elimination half-live (t1/2) values were not evalu-
able, and for that reason, those data are not presented. For
the groups of 400 mg or higher, the peak DACP level was
reached 6–24 h after FM-VP4 administration (tmax), and
DASP tmax was reached 12–24 h postdose with the
exception of one subject in the 1,600 mg group who had
Table 2 Pharmacokinetic parameters of disodium ascorbyl campestanol phosphate (DACP) and disodium ascorbyl sitostanol phosphate (DASP)
in 24 subjects after a single dose of 400, 800, 1,600, or 2,000 mg FM-VP4 (DACP and DASP) in phase 1
Dose level (mg) Number t1/2 (h) Cmax (ng/mL) tmax (h) AUC 0→∞ (h.ng/mL) AUC 0→t (h.ng/mL)
DACP
400 4 79.6±42.3 100.6±25.5 10.7±3.0 8,734±3,864 5,942±2,646
800 4 46.2±21.8 144.5±43.6 12.1±0.1 7,672±2,479 5,787±2,045
1,600 4 35.9±11.1 175.6±106.5 7.9±3.2 11,736±11,455 9,314±10,910
2,000 4 64.0±28.3 190.9±47.2 18.3±6.4 17,179±5,685 11,414±4,318
DASP
400 4 77.3±11.6 247.9±55.1 12.1±0.1 28,142±7,153 21,115±5,255
800 4 52.2±19.0 339.7±86.9 12.1±0.1 28,872±8,183 22,907±9,382
1,600 4 53.0±14.9 344.3±225.8 24.9±21.6 39,029±38,428 30,243±30,624
2,000 4 43.6±21.8 495.9±89.0 18.5±6.6 35,642±16,584 29,204±14,549
Mean±standard deviation
t1/2 half-life in plasma, Cmax peak concentration, tmax time to reach peak concentration, AUC 0→t area under the concentration time curve where t is
the last time of blood sampling at 168 h (7 days) after treatment
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Fig. 2 Mean low-density lipo-
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28 days of treatment with
placebo or 100, 200, 400, and
800 mg/day FM-VP4 (disodium
ascorbyl campestanol phosphate
and disodium ascorbyl sitostanol
phosphate) and after 14 days
of follow-up
Eur J Clin Pharmacol (2008) 64:651–661 657at max of 49 h (Table 2). Mean t1/2 of all eligible subjects
was 57 h (2–3 days), which ranged from 16 to 134 h for
DACP and from 29 to 90 h for DASP.
AUC0→t strongly correlated with the dose (400–
2,000 mg) of FM-VP4 for DACP (R
2=0.93) and DASP
(R
2=0.90). However, AUC increased in a lower than dose-
proportional manner. Between 400 mg and 2,000 mg,
DACP and DASP AUC increased approximately twice and
1.3 times, respectively, when the dose was increased
fivefold (Table 2).
In phase 2, trough DACP and DASP concentrations
were at or near steady-state levels by day 8 in the subset of
subjects per active dose group who were hospitalized and
sampled during the first week of dosing (Fig. 3). The mean
concentrations for all subjects in each cohort on day 8 were
about the same as the mean concentrations on day 28, at the
Table 3 Concentrations of plant sterols and sterols in 100 subjects after 4 weeks of treatment with 100, 200, 400, or 800 mg/day FM-VP4
(disodium ascorbyl campestanol phosphate and disodium ascorbyl sitostanol phosphate) or placebo in phase 2
Plant stanol
or sterol
Dose level (mg) P value
Placebo (n=20) 100 (n=20) 200 (n=20) 400 (n=20) 800 (n=20)
ng/mL
Sitostanol Baseline 77.9±33.3 79.6±30.8 90.4±32.9 75.0±28.3 63.8±19.2
Day 28 102.5±39.2 104.2±38.3 132.5±56.3 178.3±63.8 168.3±44.6
% Change 41±58 37±46 48±37 159±99 178±83 <0.0001
Campestanol Baseline 116.0±84.6 91.0±36.6 104.3±81.7 100.7±57.2 83.4±18.9
Day 28 140.9±77.3 107.1±36.6 134.1±78.9 156.2±72.5 150.2±37.9
% Change 39±70 21±22 43±50 70±61 87±57 0.002
Sitosterol Baseline 2,998.3±1,842.5 3,579.3±2,084.3 2,715.0±10,725.8 2,704.3±1,071.2 2,276.3±993.2
Day 28 3,036.0±1,164.9 3,782.1±2,377.9 2,744.9±1,256.1 3,138.4±1,632.7 2,316.9±734.4
% Change 35±147 5±20 2±23 17±40 10±38 0.61
Campesterol Baseline 3,275.2±2,017.2 3,699.1±1,914.8 2,850.4±1,289.0 2,791.1±1,403.2 2,370.8±1,036.6
Day 28 3,212.3±1,375.9 3,870.2±2,252.6 3,002.7±1,439.2 3,031.5±1,500.1 2,416.9±917.6
% Change 16±80 4±22 6±19 12±35 8±35 0.91
Mean±standard deviation. Differences between all treatment groups were analyzed by using analysis of variance
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Fig. 3 Mean trough concentrations of disodium ascorbyl sitostanol
phosphate (DASP) and disodium ascorbyl campestanol phosphate
(DACP) during 28 days of dosing and 14 days postdosing follow-up.
The dots of days 2–5 represent the 16 hospitalized subjects on FM-
VP4 (DACP and DASP), whereas the dots of days 8, 28, and 42
represent all 80 subjects on FM-VP4. DASP and DACP were not
present in plasma at day 1 (baseline), and DACP concentrations were
mostly below detection limit during the first 5 days of intake in the
100-mg group. The mean levels of DASP in the 100-mg group and
DACP in the 200-mg group were below the lower limit of
quantification (LLOQ) because some of the subjects had levels below
the LLOQ, which were regarded as 0 ng/ml
658 Eur J Clin Pharmacol (2008) 64:651–661end of the treatment period. At the end of the follow-up
period, 14 days after the final dose, DASP was present in
the plasma of most or all of the subject plasma samples in
the 200-, 400-, and 800-mg groups. DACP was mainly
present in plasma samples of most subjects in the 800-mg
group. The majority of plasma samples for DACP in the
100- and 200-mg groups and for DASP in the 100-mg
group were below detection limit 14 days after follow-up.
DASP and DACP concentrations increased in a less than
dose-proportional manner compared with baseline on days
8 and 28, as well as on day 42, 14 days after treatment.
Plant sterol and stanol concentrations
In phase 1, concentrations of campestanol and sitostanol
did not change within 24 h and 7 days after a single dose of
FM-VP4. Also, concentrations of campesterol and β-
sitosterol were not affected after a single dose of FM-VP4
(data not shown).
In phase 2, sitostanol and campestanol apparently rose in
a dose-dependent fashion over the 28-day time period, with
the maximal percent change from baseline being 87% for
campestanol and 178% for sitostanol in the 800-mg group
(Table 3). Campesterol and sitosterol did not change from
baseline to day 28 (Table 3).
Discussion
In this study, we showed that a single dose of 100–2,000 mg
as well as 4-week treatment in doses of 100–800 mg of FM-
VP4 administered to moderate dyslipidemic men was well
tolerated and safe. Furthermore, 4-week treatment of FM-
VP4 reduced LDL-C levels by 6–7% compared with
baseline or by 9–11% compared with placebo.
The main treatment—emergent adverse events were
dizziness, headache, and fatigue after a single administra-
tion and headache after multiple-dose administration of the
drug. All symptoms resolved spontaneously, and subjects
receiving placebo also reported these symptoms. As there
was no difference in the incidence between active and
placebo groups, it is unlikely that the treatment-emergent
adverse events were due to FM-VP4.
No drug-related abnormalities could be identified by
laboratory safety tests. In phase 1, one subject receiving
100 mg of FM-VP4 showed a decrease in WBC count 24 h
after treatment, but this was considered unrelated to the
study drug and returned to normal 7 days after treatment. In
phase 2, one subject in the 100-mg group and one in the
800-mg group also showed low WBC counts, but these
abnormalities were already present at baseline. One subject
in the placebo group but also one in the 400-mg group
showed increased CK levels at one visit. However, we think
this is no reason for concern. First of all, the patient in the
400-mg group had no complaints. Second, the levels had
returned to normal by the next visit without medication
discontinuation. Because no adverse events have been
reported for plant sterols in general [8], we think this
single CK increase was likely to be a chance finding. In
addition, five subjects from various dose groups showed a
hemoglobin decrease at one of the visits. These decreases
were nonpersistent, and levels had returned to normal by
subsequent visits. No EKG or hemodynamic abnormalities
were detected after administration of FM-VP4. Also, no
liver or kidney abnormalities were identified. Thus, in terms
of safety tests, there was no evidence that treatment with
FM-VP4 caused any acute or delayed toxicity.
In phase 1, DACP and DASP were absorbed slowly into
plasma, with a tmax of approximately 12 h for both
components. Clearance was also rather slow, with the
average elimination t1/2 of 57 h. Furthermore, t1/2 from
phase 1 can be used to estimate the time to reach steady-
state concentration levels by calculating three times t1/2,
which is 3×57=171 h, or 7.1 days. This estimated time to
reach steady state corresponds with phase 2 data that
showed a steady state after approximately 8 days, as the
mean trough concentration at day 8 was similar to the mean
trough concentration after 4 weeks of treatment.
The low plasma concentrations of DACP and DASP
suggest low bioavailability of FM-VP4 in humans. This is
supported by findings with other plant sterol structures. The
bioavailability from 600 mg unesterified soy plant stanols
was only 0.04% for sitostanol and 0.15% for campestanol
[22], and in another study, the absorption of campestanol
from a margarine spread containing 540 mg campestanol as
fatty acid esters was 5.5% in healthy subjects [23]. In both
studies, absorption of plant sterols was measured by
intravenous injection and oral administration of labeled
isotopes in the fasting state [22, 23]. As we have not
administered labeled FM-VP4 intravenously, we were not
able to estimate the bioavailability of FM-VP4 in humans
and to investigate whether the esterified ascorbate group
affects its absorption. Future studies with FM-VP4 are
needed to assess the bioavailability of FM-VP4 in humans.
Repeated doses of FM-VP4 in phase 2 appeared to in-
crease sitostanol levels in plasma by up to 178% and cam-
pestanol by 87%, whereas corresponding sterol components
did not change. This rise in campestanol and sitostanol
appeared to increase with dose but in a less than pro-
portional manner. Furthermore, the difference in increase
from baseline between sitostanol and campestanol was
consistent with the difference in plasma concentrations for
DASP and DACP of approximately 2:1, which was most
clear in the 400- and 800-mg groups. We speculate that
conversion of DASP and DACP to free stanols may have
occurred in vivo or that FM-VP4 alters the metabolism of
Eur J Clin Pharmacol (2008) 64:651–661 659plant stanols. Nevertheless, the absolute increase in total
stanol levels remains relatively small, as the stanol
contribution is <5% of total levels (Table 3). Therefore,
the clinical relevance of such increases is probably limited.
Based on our data, we may speculate on the mechanism
by which FM-VP4 exerts its LDL-C-lowering effect. Plant
sterols and stanols are thought to compete with cholesterol
for incorporation into mixed micelles, the vehicles that
transport sterols to the enterocyte. In the case of FM-VP4,
the solubility of plant stanols for the mixed micelles has been
improved by the addition of the hydrophilic ascorbyl residue
to the hydrophobic campestanol and sitostanol tail through a
phosphodiester linkage (FM-VP4). In fact, this new structure
allowed self-assembly into micelle structures in aqueous
media in the absence of bile salts [24]. Although the
assembly of micelles by means of FM-VP4 has never been
directly compared with other types of plant sterols, the
incorporation of plant stanols and sterols as well as
cholesterol into mixed micelle normally requires the
addition of bile salts in vitro and in vivo. Furthermore, in
animals, FM-VP4 was shown to be more potent than
unesterified plant stanols in a direct comparison when
administered in the diet [16]. The results of the current
clinical trial in humans showed that FM-VP4 lowered LDL-
Cb y6 –7% compared with baseline, whereas the control
group showed a 3–4% increase in plasma LDL-C levels.
This means that compared with placebo, FM-VP4 showed
LDL-C decreases of 9–11% when administered at 400–
800 mg/day over 4 weeks. This effect was also reached
with plant sterol and stanol esters, but at doses that were
two to three times higher than the currently used doses of
FM-VP4 [8]. Thus, the higher solubility of FM-VP4 into
mixed micelles may lead to a more efficacious competition
with cholesterol for incorporation into the micelles, and as a
consequence, a lower dose of FM-VP4 is required to realize
an equal LDL-lowering effect compared with plant sterol
and stanol esters. However, the optimal treatment dose and
duration, schedule and formulation for FM-VP4 have yet to
be determined. On the other hand, it has also been suggested
that, in addition to competition with cholesterol for incorpo-
ration into the micelles, plant sterol and stanol esters also
may activate liver X receptor (LXR) target genes within the
enterocyte [25]. It is unknown whether DACP and DASP
activate such genes within the enterocyte or whether there
may be systemic effects or additional mechanisms to
decrease cholesterol absorption. Further research is needed
to elucidate the mechanism by which several types of plant
sterol and stanol esters lower LDL-C levels.
In conclusion, this study demonstrated that single and
multiple doses of FM-VP4 for 4 weeks are safe and well
tolerated by moderately hypercholesterolemic subjects.
Furthermore, the higher doses of FM-VP4 significantly
reduce LDL-C levels by 6–7% compared with baseline or
by 9–11% when compared with placebo. The pharmacoki-
netics showed that DACP and DASP are absorbed and
cleared slowly but that the absolute quantity of drug
absorbed is low, as suggested by the low plasma concen-
trations of DACP and DASP. This study suggests that
FM-VP4 merits further investigation as an alternative for
treating hyperlipidemia.
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